Sirolimus Based Therapy in Live Donor Renal Transplantation: A Prospective Randomized Study
|Full paper||Not Available|
The present work aimed to study safety and efficacy of sirolimus in combination with either low dose tacrolimus or mycophenolate mofetil in live donor kidney transplant recipients. A total of 80 patients of either sex aging 18 years with end-stage renal disease who had undergone live donor renal allotransplantation were recruited into the study. They were randomly divided into two groups; group A patients received sirolimus in a dose of 10 mg/day for 3 days after surgery then maintained on 5 mg/day. In addition, they received tacrolimus and steroids. Group B patients received sirolimus in a dose of 10 mg/day, mycophenolate mofetil and steroids. All patients were followed up for 12 months clinically and by laboratory, radiologic and histopathologic evaluation. The study showed that excellent one year kidney transplant outcomes can be achieved by sirolimus administration especially with avoidance of calcineurin inhibitors. Longer follow-up is required to study the impact on graft integrity and eventual graft survival and chronic rejection rates.